ARHGEF10L: A Potential Drug Target and Biomarker (G55160)

Target Name: ARHGEF10L

NCBI ID: G55160

ARHGEF10L

ARHGEF10L: A Potential Drug Target and Biomarker

ARHGEF10L, also known as Rho GTPase 10 like, is a protein that plays a crucial role in various cellular processes. It is a member of the Rho GTPase family, which is a well-known protein that plays a vital role in regulating cell signaling pathways.Expression and function of ARHGEF10L have been extensively studied, and its potential as a drug target and biomarker have been proposed.

Potential Drug Target

ARHGEF10L has been identified as a potential drug target due to its involvement in various cellular signaling pathways. It has been shown to regulate the activity of several kinases, including PDGF signaling pathway, which is known to play a crucial role in cancer progression. Additionally, ARHGEF10L has been shown to regulate the activity of several transcription factors, including NF-kappa-B signaling pathway, which is known to contribute to various diseases, including cancer.

Potential Biomarker

ARHGEF10L has also been identified as a potential biomarker for various diseases, including cancer. Its expression has been shown to be downregulated in various types of cancer, including breast, lung, and colon cancer. Additionally, its activity has been shown to be associated with cancer progression and poor prognosis. Therefore, it has the potential to serve as a biomarker for cancer diagnosis, prognosis, and treatment.

Animal Model

To further evaluate the potential of ARHGEF10L as a drug target and biomarker, several studies have been conducted in animals. For instance, researchers have shown that ARHGEF10L can be a druggable protein with small molecule inhibitors. In addition, several studies have shown that ARHGEF10L can be downregulated by small molecules, including inhibitors of the protein's activity.

In addition, researchers have also shown that ARHGEF10L is a good candidate for an anti-cancer drug. They have used various techniques, including xenografts, to show that ARHGEF10L can be a potent anti-cancer drug in animals, especially when combined with inhibitors of the protein's activity.

Conclusion

In conclusion, ARHGEF10L is a protein that has been extensively studied for its involvement in various cellular signaling pathways. Its potential as a drug target and biomarker have been proposed due to its involvement in cancer progression and its expression downregulation in various types of cancer. Further studies are needed to confirm its potential as a drug and to develop more effective therapies based on its targetings.

Protein Name: Rho Guanine Nucleotide Exchange Factor 10 Like

Functions: Acts as guanine nucleotide exchange factor (GEF) for RHOA, RHOB and RHOC

The "ARHGEF10L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARHGEF10L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets